Literature DB >> 21842479

Aloe vera juice: IC₅₀ and dual mechanistic inhibition of CYP3A4 and CYP2D6.

Ane Djuv1, Odd Georg Nilsen.   

Abstract

The aim of this study was to evaluate the inhibitory potency (IC₅₀ values) of ethanol extracts of two commercially available aloe vera juice (AVJ) products, on CYP3A4 and CYP2D6 activities in vitro and to determine if such inhibitions could be mechanism-based. Recombinant human CYP3A4 and CYP2D6 enzymes were used and the activities were expressed by the metabolism of testosterone and dextromethorphan with ketoconazole and quinidine as positive inhibitor controls, respectively. The formed metabolites were quantified by validated HPLC techniques. Time- and NADPH- dependent inhibition assays were performed to evaluate a possible mechanism-based inhibition. One of the AVJ extracts showed about twice the inhibitory potency towards both CYP enzymes over the other with IC₅₀ values of 8.35 ± 0.72 and 12.5 ± 2.1 mg/mL for CYP3A4 and CYP2D6, respectively. The AVJ was found to exert both CYP mediated and non-CYP mediated inhibition of both CYP3A4 and CYP2D6. This dual mechanistic inhibition, however, seems to be governed by different mechanisms for CYP3A4 and CYP2D6. Estimated IC₅₀ inhibition values indicate no major interference of AVJ with drug metabolism in man, but the dual mechanistic inhibition of both enzymes might be of clinical significance.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21842479     DOI: 10.1002/ptr.3564

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  3 in total

Review 1.  A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products.

Authors:  Andrew Stolbach; Karolina Paziana; Harry Heverling; Paul Pham
Journal:  J Med Toxicol       Date:  2015-09

2.  The co-use of conventional drugs and herbs among patients in Norwegian general practice: a cross-sectional study.

Authors:  Ane Djuv; Odd Georg Nilsen; Aslak Steinsbekk
Journal:  BMC Complement Altern Med       Date:  2013-10-30       Impact factor: 3.659

3.  Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment.

Authors:  Clemens P J G Wolf; Tobias Rachow; Thomas Ernst; Andreas Hochhaus; Bijan Zomorodbakhsch; Susan Foller; Matthias Rengsberger; Michael Hartmann; Jutta Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-06       Impact factor: 4.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.